IDH1 and acute myeloid leukemia: In a pre-planned interim analysis of the phase 2 component of the study, 153 IDH1 inhibitor naive patients with R/R IDH1-mutant AML were treated with olutasidenib monotherapy at a dose of 150 mg twice daily for continuous 28-day cycles [77].